For US residents only.

OPZELURA is a prescription medicine used on the skin (topical) for the treatment of the type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older. The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
Nonsegmental Vitiligo
Change condition 
OPZELURA Vitiligo Homepage
Copay Savings page
Nonsegmental Vitiligo
Change condition 
Copay Savings page
Book a virtual appt now
Opzelura® On Trac™ Patient Support Program
Opzelura® On Trac™ Patient Support Program

The program that’s truly there for you

The OPZELURA On TracTM patient support program is all about making the most of your treatment support experience. Designed for people with nonsegmental vitiligo who are prescribed OPZELURA, the program connects you with resources and guidance throughout the treatment journey. That includes navigating insurance coverage, exploring savings options, getting access to OPZELURA, staying on track, and sharing progress with your healthcare provider. With the patient support program, you can take comfort that you’ll have help along your treatment journey with OPZELURA. Imagine that.

Find savings and financial assistance

Save with a copay savings card

ELIGIBLE* PATIENTS WITH COMMERCIAL INSURANCE MAY PAY AS LITTLE AS $0 PER TUBE FOR YOUR OPZELURA PRESCRIPTION AND REFILLS.

There are 3 ways to get a card—download your card directly, send it to your email, or get it in a text!

GET COPAY SAVINGS CARD

*Eligibility required. For use only with commercial prescription insurance. The card may not be used if the patient is enrolled in a government-funded prescription insurance program or if they pay cash for their prescription. Individual out-of-pocket cost may vary. Maximum benefits per tube and per calendar year apply. Must be used for an FDA-approved indication. Additional Terms and Conditions apply.

 
OPZELURA Copay Savings Card
 

FINANCIAL ASSISTANCE FOR THE UNINSURED OR UNDERINSURED

If you are uninsured or have Medicare Part D coverage and cannot afford OPZELURA, IncyteCARES may be able to help. Through the Patient Assistance Program, you may be eligible* to receive OPZELURA at no cost. You are considered uninsured if you have no prescription insurance.

To learn more, visit the IncyteCARES site or call 1-800-583-6964, Monday through Friday, 8 AM-8 PM ET.

GET SUPPORT

*Terms and Conditions apply. Terms of the Patient Assistance Program may change at any time.

Accessing OPZELURA

Hear real-world experiences navigating insurance coverage and savings options with OPZELURA.

Watch Angie's Perspective video

ANGIE'S PERSPECTIVE: 
SUPPORTING PATIENTS’ ACCESS TO OPZELURA

Hear about accessing OPZELURA from Angie, a professional medication access coordinator.

Watch Alicia video

ALICIA'S STORY: 
ACCESSING OPZELURA AS A PATIENT

OPZELURA patient Alicia shares her journey to securing access to her treatment.

Watch Alicia and Angie video

ALICIA AND ANGIE: 
PERSPECTIVES ON ACCESSING OPZELURA

An OPZELURA patient and a medication access coordinator discuss living with—and treating—nonsegmental vitiligo.

FIND OUT HOW TO TRACK YOUR TREATMENT

stay on track with treatment navigator patient education program

Treatment Navigators are trained medical professionals who offer helpful advice, regular check-ins, and personalized support to help you understand and follow your OPZELURA treatment plan for managing nonsegmental vitiligo.

Treatment Navigators are provided by Incyte and do not work under the direction of your healthcare provider (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice.

Get connected

Track your progress even on-the-go

Our treatment tracking app can help you monitor progress with OPZELURA and document your treatment journey wherever you are.

Incyte, makers of OPZELURA, is happy to offer a tracking tool.

 
 
 

Journal

Record your thoughts, feelings, and results in a downloadable log as you pursue what's yours

Download journal

Habit Tracker

Chart your progress by checking off each day of completed treatment

Download Tracker

Find answers through learning sessions

join onward opzelura.

These webinars are designed to help people living with nonsegmental vitiligo and their loved ones learn about the first FDA-approved medication for this condition.

Ask questions about OPZELURA and participate along with others who are living with nonsegmental vitiligo to learn more about this condition and find support options fit for you.

This webinar is intended for US residents only and does not provide medical advice.

REGISTER FOR AN UPCOMING WEBINAR

FREQUENTLY ASKED QUESTIONS ABOUT GETTING OPZELURA

Every insurance plan is different, but Incyte, the maker of OPZELURA, offers a copay savings card for eligible patients, in addition to other programs that can help. Learn more about how to afford OPZELURA.

Your healthcare provider may use a pharmacy that offers services beyond what your typical pharmacy provides in order to help you gain access to OPZELURA.

If you are notified that your prescription for OPZELURA is not covered, don’t be alarmed. Be sure to understand the denial reason. A denial is often due to information on the insurance paperwork that was missing or incorrect. When this happens, your healthcare provider can appeal the denial by following the plan’s appeal process. Stay in close contact with your healthcare provider to make sure they have all relevant information. Contact your insurance plan with any questions around the denial and their appeal process.

Most insurance providers require a “prior authorization” (PA) to approve an OPZELURA prescription. A prior authorization asks your healthcare provider to submit additional information to confirm you're an appropriate candidate for OPZELURA. Processing the request can take time, so you may not be able to get OPZELURA from your pharmacy on the same day your healthcare provider gives you a prescription.

If you don't hear back within 5 days about your OPZELURA prescription, contact your healthcare provider. Ask if it would be helpful for you to call your insurance plan directly.

Be sure to direct questions about your unique treatment plan to your healthcare provider.

IMPORTANT SAFETY INFORMATION AND INDICATION
Indication and Usage

OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

It is not known if OPZELURA is safe and effective in children less than 12 years of age with nonsegmental vitiligo.

Important Safety Information

OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.

Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), low white blood cell counts (neutropenia, lymphopenia, leukopenia). Your healthcare provider may do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have or have had hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired.
  • have ever had any type of cancer, or are a current or past smoker
  • have had a heart attack, other heart problems, or a stroke
  • have had blood clots in the veins of your legs or lungs in the past
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or www.opzelura.pregnancy.incyte.com.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack, blood clot, or stroke while using OPZELURA, including:
  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  • weakness in one part or on one side of your body
  • slurred speech
  • swelling, pain, or tenderness in one or both legs
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.

.